NCT07056790View on ClinicalTrials.gov

Research on the Application of 68Ga-PSMA-CYC PET Imaging in the Diagnosis, Staging, and Restaging of Prostate Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions
Prostate CA
Interventions
DRUG

68Ga-PSMA-CYC

Each prostate cancer patient underwent a 68Ga-PSMA-CYC (3-4 mCi) PET/CT scan, as well as a 68Ga-PSMA-617 (3-4 mCi) or 68Ga-PSMA-11 (3-4 mCi) PET/CT scan, with the time interval between the two scans not exceeding one week.

DRUG

CYC

The dose will be 3-4mCi given intravenously.

Trial Locations (1)

350005

RECRUITING

The First Affiliated Hospital of Fujian Medical University, Fuzhou

All Listed Sponsors
lead

First Affiliated Hospital of Fujian Medical University

OTHER